Investigational Drug Information for SAR443122
✉ Email this page to a colleague
What is the development status for investigational drug SAR443122?
SAR443122 is an investigational drug.
There have been 3 clinical trials for SAR443122.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 7th 2022.
The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for SAR443122
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 12 |
WIPO Patent Applications | 3 |
Japanese Patent Applications | 1 |
Clinical Trial Progress | Phase 1 (2022-10-07) |
Vendors | 0 |
Recent Clinical Trials for SAR443122
Title | Sponsor | Phase |
---|---|---|
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | Sanofi | Phase 2 |
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus | Sanofi | Phase 2 |
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 | Sanofi | Phase 1 |
Clinical Trial Summary for SAR443122
Top disease conditions for SAR443122
Top clinical trial sponsors for SAR443122
US Patents for SAR443122
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |